STOCK TITAN

Axsome Therapeutics Inc - AXSM STOCK NEWS

Welcome to our dedicated news page for Axsome Therapeutics (Ticker: AXSM), a resource for investors and traders seeking the latest updates and insights on Axsome Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Axsome Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Axsome Therapeutics's position in the market.

Rhea-AI Summary
Axsome to report Q3 2023 financial results and host conference call on Nov. 6, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
conferences earnings
-
Rhea-AI Summary
Axsome Therapeutics joins global narcolepsy advocacy community to raise awareness of World Narcolepsy Day
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
none
-
Rhea-AI Summary
Axsome Therapeutics CEO to participate in investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
conferences
Rhea-AI Summary
Axsome Therapeutics, Inc. (NASDAQ: AXSM) reported strong 2Q 2023 financial results, with $46.7 million in total product revenue, 76% growth in Auvelity® net product sales, and $19.1 million in Sunosi® net product revenue. The company also received positive FDA feedback for new potential indications for solriamfetol, initiating Phase 3 trials for binge eating disorder and shift work disorder in the next two quarters.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
-
Rhea-AI Summary
Axsome Therapeutics, Inc. will report its financial results for Q2 2023 on Aug. 7, 2023, before the opening of the U.S. financial markets. The management team will host a conference call at 8:00 a.m. Eastern Time on Aug. 7, 2023, to discuss these results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.06%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.06%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
conferences
Axsome Therapeutics Inc

Nasdaq:AXSM

AXSM Rankings

AXSM Stock Data

3.26B
34.88M
17.12%
83.32%
16.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About AXSM

axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.